Key Takeaways
- Harrow has re-launched Verkazia, a cyclosporine ophthalmic emulsion indicated for the treatment of vernal keratoconjunctivitis (VKC)
- Physicians highlighted the need for steroid-sparing therapies that target the underlying inflammatory mechanisms of VKC, particularly in pediatric patients
- The company is supporting the re-launch with physician education, patient access, and affordability initiatives
Harrow announced the re-launch of Verkazia (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment indicated for vernal keratoconjunctivitis (VKC).
“The re-launch of Verkazia underscores our commitment to advancing care in underserved ophthalmic conditions,” said Mark L. Baum, CEO of Harrow. “VKC is a clinically significant, yet highly underdiagnosed disease, affecting a vulnerable patient population, where the central challenge has not been clinical efficacy, but consistent access to therapy. Our focus with this re-launch is straightforward: ensure dependable supply, remove access barriers, and enable physicians and patients to reliably obtain this important, evidence-based, and, most importantly, steroid-sparing treatment for long-term disease management.”
VKC is a chronic, potentially sight-threatening condition characterized by significant ocular inflammation. Patients often experience severe itching, pain, photophobia and tearing, and in some cases may develop corneal damage. The disease typically begins in childhood and can persist through adolescence, with seasonal flare-ups and occasional continuation into adulthood.
Verkazia is a topical calcineurin inhibitor immunomodulator that targets the inflammatory pathways underlying VKC. According to Harrow, guidelines increasingly support earlier use of calcineurin inhibitors to reduce inflammation, minimize corticosteroid dependence and improve long-term outcomes.
“There remains a substantial need for effective, long-term VKC treatment options, particularly those that reduce steroid exposure,” said Elsa Sheerer, OD, pediatric optometrist at NYC Health + Hospitals. “The availability of a targeted cyclosporine formulation is an important advancement for clinicians managing this complex disease.”
Harrow noted that growing awareness of VKC and increasing emphasis on early disease-modifying treatment have created a significant opportunity to improve diagnosis and long-term management of the condition. The company said its commercial strategy for Verkazia includes physician education programs, patient access support and affordability initiatives designed to improve treatment adoption and continuity of care.
Santen received FDA approval Verkazia for VKC in children and adults in 2021. Harrow acquired the US and Canadian commercial rights to the drug in 2023.
Clinicians interested in prescribing Verkazia can obtain additional information through Harrow's customer support resources and product website.
